Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan

CEN Case Reports
Hirayasu KaiKunihiro Yamagata

Abstract

We report here two cases of autosomal dominant polycystic kidney disease (ADPKD) with renal dysfunction that were treated with tolvaptan. Case 1 was a 47-year-old man with a glomerular filtration rate (GFR) of 17.0 ml/min/1.73 m(2) who received tolvaptan treatment (30 mg/day). After treatment, kidney pain was alleviated, and the estimated GFR (eGFR) decline improved from -9.84 ml/min/1.73 m(2) per year to -4.08 ml/min/1.73 m(2) per year, respectively. The rate of increase in total kidney volume was reduced from 18 % per year before treatment to 4 % per year following tolvaptan administration. Case 2 was a 44-year-old man with a GFR of 22.6 ml/min/1.73 m(2), and the eGFR decline improved from -5.76 ml/min/1.73 m(2) per year before treatment to -3.12 ml/min/1.73 m(2) per year following tolvaptan treatment (30 mg/day). The rate of increase in total kidney volume was also decreased from 10 % per year before treatment to -7 % per year following tolvaptan administration. These results suggested that tolvaptan may be effective in impeding kidney function aggravation and kidney volume increase in ADPKD patients with advanced renal dysfunction.

References

Jun 5, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Godela M Fick-BrosnahanRobert W Schrier
Nov 25, 2003·Kidney International·Bernard F KingUNKNOWN Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP)
May 19, 2006·The New England Journal of Medicine·Jared J GranthamUNKNOWN CRISP Investigators
Apr 17, 2007·Lancet·Vicente E TorresYves Pirson
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Jared J GranthamVicente E Torres
Oct 26, 2007·Kidney International·J J GranthamK T Bae
Mar 12, 2010·Advances in Chronic Kidney Disease·Peter C Harris, Sandro Rossetti
Nov 6, 2012·The New England Journal of Medicine·Vicente E TorresUNKNOWN TEMPO 3:4 Trial Investigators
Nov 28, 2012·Nature Reviews. Nephrology·Rebecca Kelsey
Jul 19, 2013·Clinical and Experimental Nephrology·Eiji HigashiharaToshiaki Nitadori
Sep 18, 2013·Annals of Internal Medicine·Kevin F EricksonJeremy D Goldhaber-Fiebert
Feb 27, 2014·The Journal of Pharmacology and Experimental Therapeutics·Miki AiharaYoshitaka Yamamura
Nov 18, 2014·The New England Journal of Medicine·Robert W SchrierUNKNOWN HALT-PKD Trial Investigators

❮ Previous
Next ❯

Citations

Dec 4, 2019·Combinatorial Chemistry & High Throughput Screening·Xuan XieXin-Ran Wang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
François Jouret, Jean-Marie Krzesinski
The New England Journal of Medicine
Vicente E TorresFrank S Czerwiec
© 2022 Meta ULC. All rights reserved